I-CreI

New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision BioSciences’ ARCUS In Vivo Genome Editing

Retrieved on: 
Tuesday, May 11, 2021

ARCUS is based on a naturally occurring genome editing enzyme, I-CreI that evolved in the algae Chlamydomonas reinhardtii to make highly specific cuts in cellular DNA.

Key Points: 
  • ARCUS is based on a naturally occurring genome editing enzyme, I-CreI that evolved in the algae Chlamydomonas reinhardtii to make highly specific cuts in cellular DNA.
  • ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.
  • Using ARCUS, the Company\xe2\x80\x99s pipeline consists of multiple \xe2\x80\x9coff-the-shelf\xe2\x80\x9d CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist.
  • For more information about Precision BioSciences, please visit www.precisionbiosciences.com.\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.